Axsome Therapeutics (AXSM)

• Market cap: $5.9B
• 1 day: 1.3%
• 5 days: -3.68%
• 1 month: 6.31%
• 3 months: 14.82%
• 6 months: -5.31%
• Year to date: 35.3%
• 1 year: 29.06%
• 5 years: 44.69%
• 10 years: 1,251.72%
• Sector: Healthcare
• Industry: Biotechnology

About: Axsome Therapeutics Inc is a clinical-stage biopharmaceutical company. It is engaged in developing novel therapies for the management of the central nervous system, or CNS, disorders for which there are limited treatment options. Its pipeline products includes AXS-05, AXS-07, AXS-12, and AXS-14. It manages its business as one operating segment and reporting unit, which is the business of developing and delivering novel therapies for the management of CNS disorders.

Employees: 589

Fund manager confidence

Based on 2025 Q2 regulatory disclosures by fund managers ($100M+ AUM)

70% more repeat investments, than reductions

Existing positions increased: 151 | Existing positions reduced: 89

0.98% more ownership

Funds ownership: 75.87% [Q1] → 76.85% (+0.98%) [Q2]

4% less call options, than puts

Call options by funds: $66.7M | Put options by funds: $69.3M

5% less first-time investments, than exits

New positions opened: 54 | Existing positions closed: 57

2% less funds holding

Funds holding: 349 [Q1] → 341 (-8) [Q2]

8% less capital invested

Capital invested by funds: $4.32B [Q1] → $3.95B (-$366M) [Q2]

42% less funds holding in top 10

Funds holding in top 10: 12 [Q1] → 7 (-5) [Q2]

Research analyst outlook

5 Wall Street Analysts provided 1 year price targets over the past 3 months

• Low target: $150
• Avg. target: $174
• High target: $190

5 analyst ratings

• positive: 5 100%
• neutral: 0 0%
• negative: 0 0%

Wells Fargo Benjamin Burnett	$163	Overweight Assumed	3 Sep 2025
B of A Securities Jason Gerberry	$176	Buy Maintained	5 Aug 2025
RBC Capital Leonid Timashev	$189	Outperform Maintained	5 Aug 2025
Needham Ami Fadia	$150	Buy Reiterated	4 Aug 2025
Morgan Stanley Sean Laaman	$190	Overweight Assumed	3 Jul 2025